iShares Biotechnology ETF (IBB)

Key Metrics

TER 44.00% per year

Distribution policy Distributing

Fund size USD 8,123 M

Inception date February 5, 2001

Holdings 258

Fund currency USD

Fund domicile US

Provider iShares

For full official fund details, factsheets, and holdings, visit ishares.com (opens in new tab).

Historical Return

Last updated: Jun 15, 2026

1 Year +33.5% +0.2% Div

3 Years (avg.) +9.0% +0.2% Div

5 Years (avg.) +1.4% +0.2% Div

Risk & Analysis Metrics

Last updated: Jun 15, 2026

Volatility

19.24% 1 Year

19.56% 3 Years

21.63% 5 Years

23.03% 10 Years

Max Drawdown

-9.70% 1 Year

-25.06% 3 Years

-39.95% 5 Years

-39.95% 10 Years

Sharpe Ratio

1.22 1 Year

0.30 3 Years

-0.03 5 Years

0.21 10 Years

Return Triangle (Heatmap)

Last updated: Jun 15, 2026

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
2011	10.7%	20.1%	32.2%	32.6%	27.8%	18.5%	18.5%	14.2%	15.2%	16.3%	14.8%	12.1%	11.5%	10.3%	11.4%
2012		30.3%	44.5%	40.8%	32.5%	20.1%	19.9%	14.7%	15.8%	16.9%	15.3%	12.3%	11.6%	10.3%	11.4%
2013			60.3%	46.3%	33.2%	17.7%	17.9%	12.3%	13.9%	15.4%	13.7%	10.6%	10.0%	8.8%	10.1%
2014				33.6%	21.5%	6.2%	9.2%	4.6%	7.5%	10.1%	8.9%	6.1%	6.0%	5.0%	6.7%
2015					10.4%	-5.3%	2.1%	-1.6%	3.0%	6.6%	5.8%	3.1%	3.3%	2.5%	4.5%
2016						-18.8%	-1.9%	-5.3%	1.2%	5.8%	5.1%	2.1%	2.4%	1.6%	3.9%
2017							18.5%	2.2%	8.9%	13.0%	10.6%	6.1%	5.9%	4.5%	6.8%
2018								-11.8%	4.4%	11.3%	8.7%	3.8%	3.9%	2.7%	5.5%
2019									23.6%	25.0%	16.6%	8.1%	7.4%	5.3%	8.2%
2020										26.4%	13.2%	3.4%	3.6%	2.0%	5.8%
2021											1.4%	-6.5%	-3.0%	-3.3%	2.1%
2022												-13.8%	-5.1%	-4.8%	2.3%
2023													4.5%	0.0%	8.3%
2024														-4.2%	10.3%
2025															27.0%

Distributions

*by ETF Portfolio Weight Last updated: Jun 15, 2026

Profit Margin Distribution

< 0%

32%

1y 3y N/A N/A

0 - 5%

1y 3y N/A N/A

5 - 10%

1y 3y N/A N/A

10 - 15%

1y 3y N/A N/A

15 - 20%

1y 3y N/A N/A

20 - 30%

21%

1y 3y N/A N/A

30 - 40%

23%

1y 3y N/A N/A

> 40%

1y 3y N/A N/A

P/E Ratio Distribution

< 0

39%

1y 3y N/A N/A

0 - 10

1y 3y N/A N/A

10 - 15

1y 3y N/A N/A

15 - 20

15%

1y 3y N/A N/A

20 - 25

14%

1y 3y N/A N/A

25 - 35

11%

1y 3y N/A N/A

35 - 50

1y 3y N/A N/A

> 50

1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation

N/A

Undervalued

> 60%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

15 - 30%

1y 3y N/A N/A

Fair (±15%)

1y 3y N/A N/A

Overvalued

15 - 30%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

> 60%

1y 3y N/A N/A

Market Cap Size Distribution

Micro Cap

0.8%

1y 3y N/A N/A

Small Cap

7.0%

1y 3y N/A N/A

Mid Cap

22.3%

1y 3y N/A N/A

Large Cap

69.9%

1y 3y N/A N/A

Mega Cap

0.0%

1y 3y N/A N/A

Micro: < $300M Small: $300M–$2B Mid: $2B–$10B Large: $10B–$200B Mega: > $200B

Average metrics of all companies in portfolio

Last updated: Jun 21, 2026

Market
Average

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$52.8B	-
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	0.47%	2.03%
Beta Indicates the relationship between the price performance of a share and the market.	0.65	-
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	30.58	28.29
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything	-36.58	-
Profitable Companies	61%	-
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	35.05	14.56
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	8.84	8.28
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	11.24	10.72

Market
Average

Enterprise Value to EBIT Enterprise Value divided by EBIT	3.94	21.15
Enterprise Value to Revenue Enterprise value divided by revenue	9.32	8.72
Total Debt to Enterprise Value Total debt divided by enterprise value	0.06	0.05
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	0.84	0.33
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	2.14%	-6.18%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-7.4%	-117.9%
Return on Equity Equity divided by market cap.	6.65%	1.23%
Return on Assets Indicates a company's profitability in relation to its total assets.	-3.57%	3.29%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	-1.23%	3.31%

Sectors

Manufacturing	80.5%
Professional, Scientific, and Technical Services	10.6%
Health Care and Social Assistance	2.7%
Healthcare	0.6%
Financial Services	0.0%
Other	5.6%

Countries

United States	86.1%
Netherlands	4.2%
Switzerland	2.2%
United Kingdom	2.0%
Denmark	2.0%
Ireland	0.8%
Canada	0.7%
Germany	0.7%
France	0.5%
Other	0.2%
China	0.1%
Belgium	0.1%
Spain	0.1%
Singapore	0.1%
Australia	0.1%
Italy	0.1%
Luxembourg	0.0%
Other	0.0%

Limit holdings to companies in a single sector.

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

Total Investment

Weight

Gilead Sciences, Inc.

GILD - Manufacturing

Market Cap $153.66B

P/E Ratio 16.7

Dividends 2.6%

Total Investment $629.35M

Weight 7.75%

Loading details…

AMGEN Inc.

AMGN - Manufacturing

Market Cap $182.21B

P/E Ratio 23.3

Dividends 2.9%

Total Investment $609.81M

Weight 7.51%

Loading details…

Vertex Pharmaceuticals, Inc.

VRTX - Manufacturing

Market Cap $114.63B

P/E Ratio 26.5

Dividends 0.0%

Total Investment $604.63M

Weight 7.44%

Loading details…

Regeneron Pharmaceuticals, Inc.

REGN - Manufacturing

Market Cap $62.84B

P/E Ratio 14.3

Dividends 0.6%

Total Investment $585.84M

Weight 7.21%

Loading details…

Alnylam Pharmaceuticals Inc

ALNY - Manufacturing

Market Cap $37.13B

P/E Ratio 63.8

Dividends 0.0%

Total Investment $324.13M

Weight 3.99%

Loading details…

Insmed Inc

INSM - Manufacturing

Market Cap $20.76B

P/E Ratio -17.4

Dividends 0.0%

Total Investment $259.65M

Weight 3.20%

Loading details…

Argen X SE - ADR

ARGX - Manufacturing

Market Cap $54.32B

P/E Ratio 49.7

Dividends 0.0%

Total Investment $249.66M

Weight 3.07%

Loading details…

Biogen Inc

BIIB - Manufacturing

Market Cap $29.02B

P/E Ratio 21.0

Dividends 0.0%

Total Investment $200.02M

Weight 2.46%

Loading details…

Natera Inc

NTRA - Health Care and Social Assistance

Market Cap $33.14B

P/E Ratio -144.7

Dividends 0.0%

Total Investment $196.11M

Weight 2.41%

Loading details…

United Therapeutics Corp

UTHR - Manufacturing

Market Cap $22.78B

P/E Ratio 18.1

Dividends 0.0%

Total Investment $187.09M

Weight 2.30%

Loading details…

BeiGene Ltd - ADR

BGNE - Manufacturing

Market Cap $20.21B

P/E Ratio 4.0

Dividends 0.0%

Total Investment $157.14M

Weight 1.93%

Loading details…

Incyte Corp.

INCY - Professional, Scientific, and Technical Services

Market Cap $19.62B

P/E Ratio 13.7

Dividends 0.0%

Total Investment $138.16M

Weight 1.70%

Loading details…

Moderna Inc

MRNA - Manufacturing

Market Cap $25.38B

P/E Ratio -7.9

Dividends 0.0%

Total Investment $136.78M

Weight 1.68%

Loading details…

Illumina Inc

ILMN - Manufacturing

Market Cap $24.5B

P/E Ratio 29.0

Dividends 0.0%

Total Investment $136.48M

Weight 1.68%

Loading details…

Revolution Medicines Inc

RVMD - Manufacturing

Market Cap $34.65B

P/E Ratio -23.5

Dividends 0.0%

Total Investment $124.86M

Weight 1.54%

Loading details…

Roivant Sciences Ltd

ROIV

Market Cap $22.61B

P/E Ratio -73.6

Dividends 0.0%

Total Investment $100.9M

Weight 1.24%

Loading details…

Neurocrine Biosciences, Inc.

NBIX - Manufacturing

Market Cap $15.92B

P/E Ratio 23.8

Dividends 0.0%

Total Investment $95.84M

Weight 1.18%

Loading details…

Genmab - ADR

GMAB - Professional, Scientific, and Technical Services

Market Cap $15.51B

P/E Ratio 18.9

Dividends 0.0%

Total Investment $95.38M

Weight 1.17%

Loading details…

BridgeBio Pharma Inc

BBIO - Manufacturing

Market Cap $12.98B

P/E Ratio -17.7

Dividends 0.0%

Total Investment $91.98M

Weight 1.13%

Loading details…

Ionis Pharmaceuticals Inc

IONS - Manufacturing

Market Cap $12.25B

P/E Ratio -37.4

Dividends 0.0%

Total Investment $90.52M

Weight 1.11%

Loading details…

Key Metrics

Compare similar ETFs

Historical Return

Risk & Analysis Metrics

Volatility

Max Drawdown

Sharpe Ratio

Return Triangle (Heatmap)

Distributions

Profit Margin Distribution

P/E Ratio Distribution

Discounted Cash Flow

Market Cap Size Distribution

Portfolio Concentration

Latest News

AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus

Why Amgen Stock Is Paying Off Big For Long-Term Investors

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Average metrics of all companies in portfolio

Sectors

Countries

Stock Screener

Gilead Sciences, Inc.

Gilead Sciences, Inc.

AMGEN Inc.

AMGEN Inc.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Insmed Inc

Insmed Inc

Argen X SE - ADR

Argen X SE - ADR

Biogen Inc

Biogen Inc

Natera Inc

Natera Inc

United Therapeutics Corp

United Therapeutics Corp

BeiGene Ltd - ADR

BeiGene Ltd - ADR

Incyte Corp.

Incyte Corp.

Moderna Inc

Moderna Inc

Illumina Inc

Illumina Inc

Revolution Medicines Inc

Revolution Medicines Inc

Roivant Sciences Ltd

Roivant Sciences Ltd

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

Genmab - ADR

Genmab - ADR

BridgeBio Pharma Inc

BridgeBio Pharma Inc

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Cookie Settings